Long-acting interferon is not fast for the decline of the virus of small triad, and long-acting interferon mainly plays the efficacy of immunomodulation and anti-tumor. Long-acting interferon can bind to the alpha receptor on the cell surface and has an immunomodulatory effect, it does not have direct antiviral effect. The speed of virus decline in patients with hepatitis B minor triple yang mainly depends on the degree of immune response stimulated by the user, and usually the virus decline is not fast. Long-acting interferon can exert immunomodulatory and anti-tumor effects, and can be used for the treatment of people with a family history of liver cancer and those who expect to achieve a clinical cure. According to available studies, when surface antigen is less than 1500 IU/ml in hepatitis B infected patients treated with nucleoside analogs, the combination of long-acting interferon can lead to surface antigen conversion in about 30% of hepatitis B patients.